Troels Jordansen, Chief Executive Officer
Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.
Jan Spanholtz PhD, Chief Scientific Officer
Dr. Jan Spanholtz initiated Glycostem's research in the start-up phase in 2007 and is currently Chief Scientific Officer (CSO) of Glycostem. Dr. Jan Spanholtz has more than 15 years of expertise in research on stem cell biology and immunology at universities and within biotech companies. He is author of various peer-reviewed research articles and inventor of Glycostem's proprietary technology platform to generate oNKord® from umbilical cord blood stem cells. For Glycostem, he has set-up and managed several national and international collaborations and spearheaded clinical translational of Glycostem's NK-cell product, oNKord®. He has developed the core IP strategy for Glycostem as inventor of feeder cell free NK-cell culture method from cord blood stem cells, synthetic culture medium for NK-cells and has was also part of several other patent applications in the stem cell field.
Volker Huppert Dipl.-Ing., Chief Operating Officer
Volker Huppert is a graduated bioprocess engineer from RWTH Aachen University. Volker has participated in set-up of quality system for a medical device/biotechnology company, and has developed several clinical level reagents, disposable tubing sets and process software for cell separation and cell culture medical devices. He contributed to tubing set and process software development of a leading cell therapy manufacturing device plus managed projects and teams for the development of cell manufacturing procedures for hematopoietic stem cells and Natural Killer cells. With 20 years’ experience in a leading biotechnology company Volker has published 12 papers in peer reviewed journals and is co-inventor of 9 patent families, including methods for T cell depletion of hematopoietic stem cell products, NK cell transduction and NK cell proliferation.
Harm Hermsen PhD, Chief Regulatory and Quality Officer
Harm Hermsen is an ATMP regulatory expert. As of 2000 following his PhD graduation in Biochemistry at the University Medical Centre Radboud the Netherlands, Harm has been with the GMO office in the Netherlands where he was evaluating environmental risk assessments for gene therapies and worked as coordinator of the Dutch Gene Therapy office. He pursued his career with the Medicines Evaluation Board in the Netherlands where he worked as a senior pharmaceutical assessor. Harm was member of EMA Gene Therapy Working Party and ICH gene therapy expert group. Currently he still is member of the European Pharmacopoeia Gene Therapy Working Party. Prior to joining Glycostem Harm worked as a principal consultant for Biotech and ATMPs with Xendo. During this period he consulted in product development and regulatory affairs with some of the world’s leading companies in cell and gene therapies.
Dr Didier Haguenauer MD, ESSEC, Senior Vice President of Clinical Affairs
Prior to joining Glycostem in June 2018, Didier had an extensive experience of Clinical Research, Medical Affairs and Health Technology Assessment in the Pharma and Biotech industry for more than 25 years, including cell therapy in hematologic malignancies, small molecules and biomarkers in oncology.
His experience includes both clinical stage companies, and big Pharmas like AstraZeneca.
Marty Wulferink PhD, IP Advisor
Marty Wulferink obtained his PhD at Utrecht University on the subject of chemical induced allergy and autoimmunity. After working as a postdoctoral fellow and later as project manager for a start-up pharmaceutical/biotech company for six years, Marty joined one of the largest patent firms of the Netherlands to become Dutch patent attorney and European patent attorney. Marty has a strong background in cell biology and immunology and obtained insight in clinical pharmaceutical development. He is co-inventor on 4 patent families and has published 15 papers in peer-reviewed journals. During and after his training to become patent attorney he gained hands-on working experience in the field of advising start-up companies and universities concerning biological and/or pharmaceutical inventions, diagnostic inventions, licensing, research agreements and Third Party Rights analyses.